Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHITAL R MEHTA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1861460610
CMS profile
39379
Location
WESLEY CHAPEL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,587.13

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,587.13 86

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHITAL R MEHTA

NPI 1861460610 · CMS profile ID 39379

Allopathic & Osteopathic Physicians / Internal Medicine

WESLEY CHAPEL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861460610?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHITAL R MEHTA, NPI 1861460610, CMS profile ID 39379. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861460610?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHITAL R MEHTA, NPI 1861460610, CMS profile ID 39379. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861460610?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHITAL R MEHTA, NPI 1861460610, CMS profile ID 39379, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861460610?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $1,587.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $13.3305/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848484431 CMS
AbbVie Inc. $0.8005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635663 CMS
AbbVie Inc. $13.7205/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635669 CMS
AbbVie Inc. $4.5805/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635657 CMS
Janssen Pharmaceuticals, Inc $11.7705/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788759725 CMS
Janssen Pharmaceuticals, Inc $12.8504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788759723 CMS
Novo Nordisk Inc $17.7604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811106797 CMS
Biohaven Pharmaceuticals, Inc. $11.4804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852565321 CMS
AstraZeneca Pharmaceuticals LP $11.1604/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829462087 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.8904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820083099 CMS
Almatica Pharma LLC $25.7004/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842211323 CMS
Novartis Pharmaceuticals Corporation $16.2004/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813074947 CMS
Lilly USA, LLC $22.5304/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818699691 CMS
AstraZeneca Pharmaceuticals LP $11.5504/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830082127 CMS
GlaxoSmithKline, LLC. $19.5303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802933941 CMS
SANOFI-AVENTIS U.S. LLC $24.8603/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600069 CMS
Novo Nordisk Inc $23.9303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810989349 CMS
AbbVie Inc. $9.5103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635651 CMS
Janssen Pharmaceuticals, Inc $17.1703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788759727 CMS
AstraZeneca Pharmaceuticals LP $15.0403/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829388787 CMS
GlaxoSmithKline, LLC. $89.6103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803073017 CMS
PFIZER INC. $16.2603/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833472421 CMS
GlaxoSmithKline, LLC. $11.1403/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803185941 CMS
AbbVie Inc. $23.9602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635645 CMS
AstraZeneca Pharmaceuticals LP $19.7202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829924383 CMS
Amarin Pharma Inc. $24.2302/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815283777 CMS
Lilly USA, LLC $21.5602/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818681013 CMS
Janssen Pharmaceuticals, Inc $15.8502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788759721 CMS
GlaxoSmithKline, LLC. $16.0102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803042293 CMS
Lilly USA, LLC $18.5002/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818730959 CMS
SANOFI-AVENTIS U.S. LLC $20.0001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843599935 CMS
Merck Sharp & Dohme Corporation $20.0001/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848314789 CMS
AbbVie Inc. $11.7701/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795635639 CMS
AstraZeneca Pharmaceuticals LP $15.5801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829920603 CMS
Novartis Pharmaceuticals Corporation $15.6401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813074943 CMS
Lilly USA, LLC $23.8201/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818753803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,305.10 86
PY2020 $1,960.05 111
PY2021 $1,587.13 86
PY2022 $1,691.33 91
PY2023 $1,611.91 73
PY2024 $1,317.12 67
PY2025 $1,281.33 63

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $869,574.03 37
PY2024 Recipient $72,855.00 1
PY2024 Principal investigator $339,208.51 40
PY2023 Principal investigator $82,674.87 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,350.00 12/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185544883
Principal investigator 1 Eli Lilly and Company $269.90 11/19/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187877195
Principal investigator 1 Eli Lilly and Company $1,090.00 10/06/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187876765
Principal investigator 1 Eli Lilly and Company $22,441.68 09/08/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187877193
Principal investigator 1 Janssen Research & Development, LLC $5,328.00 08/28/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225245
Principal investigator 1 Janssen Research & Development, LLC $4,440.00 08/28/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226816
Principal investigator 1 Janssen Research & Development, LLC $1,016.00 08/26/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225229
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,465.45 07/31/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185544879
Principal investigator 1 Janssen Research & Development, LLC $12,192.00 07/28/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225644
Principal investigator 1 Janssen Research & Development, LLC $4.00 07/16/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225504
Principal investigator 1 Janssen Research & Development, LLC $40.00 07/16/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225544
Principal investigator 1 Eli Lilly and Company $270,780.00 06/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187877289
Principal investigator 1 Janssen Research & Development, LLC $562.00 06/20/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225111
Principal investigator 1 Janssen Research & Development, LLC $417.00 05/20/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226222
Principal investigator 1 Janssen Research & Development, LLC $160.00 04/28/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225535
Principal investigator 1 Janssen Research & Development, LLC $2,531.00 04/28/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226124
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $5,821.45 04/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187878577
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225008
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225292
Principal investigator 1 Janssen Research & Development, LLC $2.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225390
Principal investigator 1 Janssen Research & Development, LLC $3,780.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225442
Principal investigator 1 Janssen Research & Development, LLC $3,999.86 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225667
Principal investigator 1 Janssen Research & Development, LLC $220.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226020
Principal investigator 1 Janssen Research & Development, LLC $800.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226311
Principal investigator 1 Janssen Research & Development, LLC $3,309.75 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226357
Principal investigator 1 Janssen Research & Development, LLC $1,195.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226456
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226652
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226799
Principal investigator 1 Janssen Research & Development, LLC $44.00 04/23/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226862
Principal investigator 1 Janssen Research & Development, LLC $8,004.00 04/17/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175226659
Principal investigator 1 Janssen Research & Development, LLC $834.00 03/25/2025 Non-covered Recipient Entity
Care Access Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175225965
Principal investigator 1 Eli Lilly and Company $535.00 01/31/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878291
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,263.62 01/29/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185544881
Principal investigator 1 Eli Lilly and Company $7,796.51 01/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876749
Principal investigator 1 Eli Lilly and Company $676.88 01/22/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187876507
Principal investigator 1 Eli Lilly and Company $56,026.93 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882736
Principal investigator 1 Eli Lilly and Company $370,653.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187877281